Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

Find the latest information on Kenvue Inc. Common Stock (KVUE) insider activity and insider shares traded to make sound investments with Nasdaq.com.

Present Market Standing of Kenvue With a volume of 8,876,649, the price of KVUE is up 1.54% at $21.41. RSI indicators hint that the underlying stock may be overbought. Next earnings are expected ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Despite the recent bump, Kenvue stock has fallen by about 15% since it was spun off from Johnson & Johnson last May. The loss is extra upsetting because the benchmark S&P 500 index has risen about ...

Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Kenvue's management presented the second quarter 2024 results on August 6, 2024. Adjusted earnings per share ("EPS") were 16% better than expected , while net sales were 1.8% ahead of expectations.

Kenvue shares are up just 7% year-to-date compared to more than 23% gains in the S&P 500. Competitors Haleon HLN and Proctor and Gamble Company PG have climbed 21% and 16%, respectively, since the ...

Kenvue's stock is trading at $23.20, comfortably above key moving averages. The eight-day simple moving average sits at $22.33, the 20-day SMA is $21.87 and the 50-day SMA trails at $19.94. That's ...

Shares of Kenvue (NYSE: KVUE) got a nice bounce on Monday, Oct. 21, thanks to Starboard Value. The activist investor recently pushed the stock up by announcing a stake in the consumer goods giant ...